Christopher F Nicodemus
Research Subjects
Christopher F Nicodemus has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Birgit C Schultes
Advanced Immune Therapeutics, Inc, Charlestown, MA, USA
1 shared publication - Elizabeth Ortiz-Sánchez
Subdirection of Basic Research, National Cancer Institute of Mexico (Instituto Nacional de Cancerología, INCan) 4 , Av. San Fernando 22, Belisario Domínguez Sección 16, Tlalpan, Mexico City 14080
1 shared publication - Gustavo Helguera
Instituto de Biología y Medicina Experimental (IBYME-CONICET)
1 shared publication - Jose Rodriguez
Department of Chemistry and Biochemistry, UCLA-DOE Institute for Genomics and Proteomics, University of California, Los Angeles, California, 90095, USA
1 shared publication - Maggie Kozman
Departments of Internal Medicine
1 shared publication - Manuel L. Penichet
Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, USA
1 shared publication
Latest Publications
- 28 August 2015
- Published by Taylor & Francis in Immunotherapy
- Vol. 7 (8) , 923-939
Antibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host–tumor interaction has defined a new range of targets for antibody development. The clinical success of the checkpoint inhibitors has validated immune modulation and mobilization as a therapeutic approach. Solid cancers are distinguished from hematologic malignancies because the solid tumor stroma contains significant tumor promoting and immune dampening elements less prominent in hematologic cancer. This review highlights how engineered monoclonal antibody products are emerging as potential cornerstones of new more personalized cancer treatment paradigms that target both tumor and the stromal environment.
- 28 August 2015
- Published by Taylor & Francis in Immunotherapy
- Vol. 7 (8) , 923-939
Antibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host–tumor interaction has defined a new range of targets for antibody development. The clinical success of the checkpoint inhibitors has validated immune modulation and mobilization as a therapeutic approach. Solid cancers are distinguished from hematologic malignancies because the solid tumor stroma contains significant tumor promoting and immune dampening elements less prominent in hematologic cancer. This review highlights how engineered monoclonal antibody products are emerging as potential cornerstones of new more personalized cancer treatment paradigms that target both tumor and the stromal environment.
- Open Access
- 17 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.
- 17 April 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 195
Open AccessA novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy
Prostate cancer (PCa) is the second leading cause of cancer deaths in men in the United States. The prostate-specific antigen (PSA), often found at high levels in the serum of PCa patients, has been used as a marker for PCa detection and as a target of immunotherapy. The murine IgG1 monoclonal antibody AR47.47, specific for human PSA, has been shown to enhance antigen presentation by human dendritic cells and induce both CD4 and CD8 T-cell activation when complexed with PSA. In this study, we explored the properties of a novel mouse/human chimeric anti-PSA IgE containing the variable regions of AR47.47 as a potential therapy for PCa. Our goal was to take advantage of the unique properties of IgE in order to trigger immune activation against PCa.